tadocizumab tadocizumab tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system. it binds to integrin αiibβ3, a fibrinogen and fibronectin receptor found on platelets. the drug is designed for the treatment of patients undergoing percutaneous coronary interventions. it was developed by yamanōchi pharma america, inc. tadocizumabmonoclonal antibodytypefab fragmentsourcehumanized (from mouse)targetintegrin αiibβ3clinical dataatc codenoneidentifierscas number339086-80-5 nchemspidernoneuniir34t642cgvchemical and physical dataformulac2107h3252n562o673s12molar mass47609.17 g·mol−1 ny (what is this?) (verify)